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Abstract
Introduction ScFv(FRP5)-ETA is a recombinant antibody toxin
with binding specificity for ErbB2 (HER2). It consists of an N-
terminal single-chain antibody fragment (scFv), genetically
linked to truncated Pseudomonas  exotoxin A (ETA). Potent
antitumoral activity of scFv(FRP5)-ETA against ErbB2-
overexpressing tumor cells was previously demonstrated in vitro
and in animal models. Here we report the first systemic
application of scFv(FRP5)-ETA in human cancer patients.
Methods We have performed a phase I dose-finding study, with
the objective to assess the maximum tolerated dose and the
dose-limiting toxicity of intravenously injected scFv(FRP5)-ETA.
Eighteen patients suffering from ErbB2-expressing metastatic
breast cancers, prostate cancers, head and neck cancer, non
small cell lung cancer, or transitional cell carcinoma were
treated. Dose levels of 2, 4, 10, 12.5, and 20 µg/kg scFv(FRP5)-
ETA were administered as five daily infusions each for two
consecutive weeks.
Results No hematologic, renal, and/or cardiovascular toxicities
were noted in any of the patients treated. However, transient
elevation of liver enzymes was observed, and considered dose
limiting, in one of six patients at the maximum tolerated dose of
12.5 µg/kg, and in two of three patients at 20 µg/kg. Fifteen
minutes after injection, peak concentrations of more than 100
ng/ml scFv(FRP5)-ETA were obtained at a dose of 10 µg/kg,
indicating that predicted therapeutic levels of the recombinant
protein can be applied without inducing toxic side effects.
Induction of antibodies against scFv(FRP5)-ETA was observed
8 days after initiation of therapy in 13 patients investigated, but
only in five of these patients could neutralizing activity be
detected. Two patients showed stable disease and in three
patients clinical signs of activity in terms of signs and symptoms
were observed (all treated at doses ≥  10 µg/kg). Disease
progression occurred in 11 of the patients.
Conclusion Our results demonstrate that systemic therapy with
scFv(FRP5)-ETA can be safely administered up to a maximum
tolerated dose of 12.5 µg/kg in patients with ErbB2-expressing
tumors, justifying further clinical development.
Introduction
Aberrant expression of the epidermal growth factor receptor or
the closely related ErbB2 (HER2/neu) receptor tyrosine
kinase has been implicated in the formation of various human
malignancies [1,2], making these receptors interesting targets
for directed anticancer therapeutics. Antibodies that block lig-
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BSA = bovine serum albumin; ELISA = enzyme-linked immunosorbent assay; 
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and binding or interfere with receptor function can directly
inhibit the growth of cancer cells in addition to their potential
to direct effector cells of the immune system to the tumor [3].
With the humanized mAb Herceptin™ (trastuzumab), an
ErbB2-specific reagent for the treatment of breast carcinomas
is in clinical use. Monotherapy with the antibody or combina-
tion with chemotherapy protocols resulted in increased clinical
benefit for a significant proportion of patients with ErbB2-over-
expressing metastatic breast cancers [4,5]. Nevertheless,
responses could not be achieved in all patients with tumors
expressing high ErbB2 levels, suggesting that in addition to
enhanced expression of the target receptor, other factors such
as limited recruitment of endogenous immune effector mecha-
nisms or the presence of alternative signaling pathways in
tumor cells can also influence treatment outcome.
In contrast to such unmodified antibodies, antibody toxins are
not dependent on the inhibition of signaling or on the recruit-
ment of complement or endogenous killer cells for antitumoral
activity, but they combine antibody-mediated recognition of
tumor cells with specific delivery of a potent cytotoxic effector
molecule [6-8]. These tailor-made targeting reagents might
therefore represent a valuable alternative to unmodified mAbs,
and could complement their use in the clinic. ScFv(FRP5)-ETA
is a recombinant single-chain antibody toxin with binding spe-
cificity for ErbB2-overexpressing tumor cells [9,10]. The N-ter-
minal portion of the bacterially expressed molecule is
contributed by a single-chain antibody fragment (scFv) derived
from heavy-chain and light-chain variable domains of murine
mAb FRP5, which recognizes the extracellular domain of
human ErbB2 [11]. ScFv(FRP5)-ETA harbors a truncated
Pseudomonas aeruginosa exotoxin A (ETA, PE) fragment
(amino acids 252–613 of mature exotoxin A) at the C-termi-
nus, which is devoid of the toxin's natural cell-binding domain
[9]. Upon specific binding of the scFv domain to ErbB2 on the
surface of tumor cells, the antibody toxin is internalized by
receptor-mediated endocytosis, the enzymatic domain of the
molecule is released into the cytoplasm and ADP ribosylates
elongation factor 2, a critical component of the target cell's
translation machinery [12]. Toxin-mediated inactivation of
elongation factor 2 causes the inhibition of protein synthesis
and results in subsequent tumor cell death by apoptosis
[13,14].
Efficacy of scFv(FRP5)-ETA in the treatment of ErbB2-overex-
pressing tumors has been established in numerous preclinical
in vitro and in vivo studies. ScFv(FRP5)-ETA displayed potent
antitumoral activity in vitro against a wide range of established
and primary human tumor cells, including breast and ovarian
carcinomas [9,14,15], squamous cell carcinomas [10,16] and
prostate carcinomas [17]. In experimental animals, locally or
systemically applied scFv(FRP5)-ETA effectively inhibited the
in vivo growth of human tumor xenografts [9,10,14,16], and
murine and rat tumor cells stably transfected with human c-
erbB2 constructs [18,19]. Thereby, complete elimination of
subcutaneously growing tumors [16] and prevention of metas-
tasis formation by disseminated cancer cells [19] was
observed in some models.
Potent antitumoral activity in animal models has also been
described for antibody toxins derived from the ErbB2-specific
antibody e23 [20,21]. In cancer patients, however, intrave-
nous application of such an e23-based antibody toxin resulted
in severe liver toxicity, and effective doses could not be
reached [22]. In contrast, for the scFv(FRP5)-ETA molecule
utilizing the different FRP5 antibody domain, we could previ-
ously show that local treatment of cutaneous lesions of ErbB2-
expressing tumors by intratumoral injection of the scFv(FRP5)-
ETA molecule was well tolerated, and resulted in shrinkage or
complete regression of injected tumor nodules in the majority
of patients [23].
Here we now report the first systemic application of
scFv(FRP5)-ETA in a phase I dose-finding study in human can-
cer patients, with the objective to assess the maximum toler-
ated dose and the dose-limiting toxicity. Furthermore, we have
obtained data concerning pharmacokinetic properties of
scFv(FRP5)-ETA and its ability to induce a neutralizing anti-
body response.
Patients and methods
Patients
Patients eligible for treatment with scFv(FRP5)-ETA had to be
18 years of age or older, with ErbB2-overexpressing tumors
confirmed by immunohistochemistry (DAKO-Hercep test 3+)
or fluorescence in situ hybridization analysis, showing clinical,
radiological, or serological evidence for a progression. Other
eligibility criteria included at least one previous palliative sys-
temic chemotherapy treatment and an absence of any stand-
ard treatment option. Patients with serious illness or medical
conditions besides the diagnosis of cancer, a Karnofsky index
<60%, and immunoreactivity against scFv(FRP5)-ETA were
excluded from the study. See Table 1 for further details on
patient characteristics. The study was conducted in compli-
ance with the Helsinki Declaration [24]. The treatment proto-
col and consent form were approved by the regulatory
authorities and institutional ethics committees. Informed con-
sent was obtained from the patients before therapy.
ErbB2-specific antibody toxin
Recombinant scFv(FRP5)-ETA was produced as an experi-
mental drug under Good Manufacturing Practice conditions
and was kindly provided by Ciba Geigy AG (Basel, Switzer-
land). Bacterial expression and isolation of recombinant pro-
tein from inclusion bodies was carried out following a protocol
adapted for large-scale production from the basic procedures
described elsewhere [18]. Homogeneity of the material was
analyzed by SDS-PAGE and Coomassie staining, and the
identity of the purified protein was confirmed by immunoblot
analysis and amino acid sequencing. The content of endotox-Available online http://breast-cancer-research.com/content/7/5/R617
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ins (<10 EU/ml at 0.1 mg/ml protein), content of Escherichia
coli proteins (<11 µg/ml) and content of DNA (<20 pg/ml)
were determined following standard procedures (data not
shown). The antibody toxin was supplied as a sterile solution
at 0.3 mg/ml scFv(FRP5)-ETA in a phosphate buffer [23]. Aliq-
uots of scFv(FRP5)-ETA solution were transferred to 2 ml vials
under sterile conditions in the hospital pharmacy and were
stored at -70°C. Upon thawing and subsequent storage at
temperatures between 4°C and 8°C, scFv(FRP5)-ETA
retained full bioactivity for a minimum of 6 days (IC50 for
ErbB2-expressing Renca-lacZ/ErbB2 cells, 5–6 ng/ml)
[19,23]. For application, the required amount of antibody toxin
was thawed and kept until use for a maximum of 5 days at tem-
peratures between 4°C and 8°C.
Treatment schedule and dose levels
Experiments in mice and rats demonstrated efficacy of daily
intravenous injections of scFv(FRP5)-ETA for 10 days against
localized and metastatic tumors [18,19,25]. Based on these
data, the treatment schedule for the phase I clinical study was
developed: patients received a total of 10 intravenous infu-
sions of scFv(FRP5)-ETA on day 1, day 2, day 3, day 4, day 5,
day 8, day 9, day 10, day 11, and day 12. ScFv(FRP5)-ETA
was diluted in physiological Ringer solution to achieve a total
injection volume of 50 ml. A test dose of 10 µg intravenously
was given as a 15-min infusion on day 1. The remaining dose
was administered 4 hours later as a 15-min infusion. The dose
levels of scFv(FRP5)-ETA were 2, 4, 10, 12.5, or 20 µg/kg per
treatment day. Patients received 8 mg dexamethasone, 50 mg
Table 1
Patient characteristics
Patient Age (years), sex Cancer type Stage at diagnosis/
surgery
Sites of metastasis Prior therapy
N01 61, female Head and neck T2N2bMX Local, intrapulmonal, mediastinal Surgery, radiation, 
chemotherapy
U01 61, female Breast T2N2M1 Liver, bone Surgery, chemotherapy, 
herceptin
U02 56, female Breast T4N1bM0 Lymph node, liver, central 
nervous system, skin, bone
Surgery, radiation, 
chemotherapy, herceptin
U03 68, female Breast T3N1M0 Lymph node, bone Surgery, radiation, 
chemotherapy, herceptin, 
hormonal therapy
U04 64, female Breast T3N0M0 Local, skin, bone, intrapulmonal Surgery, chemotherapy, 
herceptin
U05 71, female Breast T1aN3cM1 Lymph node, skin Surgery, chemotherapy, 
herceptin
N03 63, female Breast T3N1bM0 Liver Surgery, chemotherapy, 
herceptin
N04 55, male Transitional cell 
carcinoma
TXNXMX Lymph node Surgery, chemotherapy, 
herceptin
N05 72, male Prostate T4N3M1 Lymph node, bone, other Surgery, hormonal therapy
N06 63, male Prostate T2bN0M0 Lymph node Surgery, chemotherapy, 
hormonal therapy
N07 74, female Breast T1N0M0 Liver Surgery, radiation, hormonal 
therapy
N09 50, female Breast T1N0M0 Lymph node, liver, bone, 
intrapulmonal, pleural
Surgery, chemotherapy
N10 45, female Breast T3bN1bMX Bone Surgery, radiation, 
chemotherapy, herceptin
N12 69, female Breast T4N3M1 Local, lymph node, skin Chemotherapy, hormonal 
therapy, immunotherapy
N13 46, female Breast TXNXMX Lymph node, liver, central 
nervous system, skin, bone
Surgery, radiation, 
chemotherapy, herceptin
N14 82, female Breast TXNXMX Liver, pleural Surgery, hormonal therapy
N15 70, female Breast T2N1MX Lymph node, skin, bone Surgery, radiation, 
chemotherapy, herceptin
N17 62, male Non small cell lung 
carcinoma
T2cN2cM1 Lymph node, bone, 
intrapulmonal
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ranitidine, and 2 mg clemastine as a supportive treatment 30
min prior to scFv(FRP5)-ETA infusion to avoid anaphylactic
reactions.
Tumor assessments
The modified Response Evaluation Criteria in Solid Tumors
were used for objective tumor response assessment in this
trial. Chest X-ray, abdominal ultrasound or computed tomogra-
phy scan, specific measurement of an indicator lesion, bone
scan, or bone X-ray in the case of hot spots in the bone scan
were performed within 3 months before therapy and on day 29
after the onset of scFv(FRP5)-ETA therapy. To ensure compa-
rability, every effort was made to use the same instrumental
examination from baseline through follow-up.
Safety evaluation
The overall proportion of patients experiencing any toxicity was
determined using the National Cancer Institute Common Tox-
icity Criteria, and the corresponding grading system was used
to grade adverse events for recording in the case report form.
For all adverse events not classified by National Cancer Insti-
tute Common Toxicity Criteria, the COSTART grading classi-
fication [26] was used (severity: 1, mild; 2, moderate; 3,
severe; and 4, life-threatening). Cardiac function was deter-
mined before treatment and was monitored by electrocardiog-
raphy, by Multiple Gated Acquisition scan, or by
echocardiography on day 22 after initiation of therapy to
assess potential cardiotoxicity.
Detection of scFv(FRP5)-ETA plasma levels by sandwich 
ELISA
Ninety-six-well microtiter plates (Greiner Bio-One, Fricken-
hausen, Germany) were coated overnight with 100 µl/well of
9 µg/ml goat anti-exotoxin A capture antibody (List Biological
Laboratories, Campbell, CA, USA) diluted in 50 mM carbon-
ate buffer, pH 9.5. After washing with PBS, the plates were
blocked for 2 hours with PBS containing 1% BSA. For stand-
ard, control or patients' samples, 100 µl/well serum diluted
1:10 with PBS containing 6 mM ethylenediamine tetraacetic
acid were added in duplicate, and were incubated for 2.5
hours at 37°C. After washing with PBS, 100 µl rabbit anti-exo-
toxin A antibody [9], diluted 1:250 in PBS, were added to
each well for 1 hour at 37°C. After another washing step,
bound rabbit antibodies were detected with 100 µl/well horse-
radish peroxidase-coupled anti-rabbit IgG antibody (Amer-
sham Biosciences, Freiburg, Germany) for 1 hour at 37°C,
after a final wash followed by 100 µl/well of 1% 3,3',5,5'-
tetramethyl-benzidine (Sigma-Aldrich, Deisenhofen, Germany)
substrate solution for 5–15 min at room temperature. Then the
reaction was stopped by adding 50 µl/well of 1 M HCl, and the
absorbance at 450 nm was measured using a Wallac Victor 2
ELISA reader (PerkinElmer Wallac, Freiburg, Germany).
Pharmacokinetic analysis
The main parameters measured were Cmax and the area under
the concentration–time curve (AUC0–5 hours) of scFv(FRP5)-
ETA at day 5, obtained from the individual concentration–time
profiles (area under the concentration–time curve by trapezoi-
dal rule) and using the software program TOPFIT®  2.0
(Fischer Verlag, Stuttgart, Germany). Furthermore, the elimina-
tion half-life and plasma clearance were determined from the
concentration–time profiles using a noncompartmental
approach from the TOPFIT Library.
Detection of circulating antibodies
Ninety-six-well microtiter plates (Greiner Bio-One) were
coated overnight with 100 µl/well of 1 µg/ml scFv(FRP5)-ETA
in PBS. After washing with PBS, the plates were blocked for
2 hours with PBS containing 1% BSA. For standard, control
or patients' samples, 100 µl/well serum diluted 1:50 with PBS
were added in duplicate, and were incubated for 3 hours at
37°C. After washing with Tris-buffered saline, 100 µl alkaline
phosphatase-coupled rabbit anti-human IgG/IgM antibody
(Sigma-Aldrich), diluted 1:2000 in PBS, were added to each
well for 1 hour at 37°C, after a final wash followed by 100 µl/
well nitrophenylpyrophosphate substrate solution at room tem-
perature. The absorbance at 450 nm was measured using a
Wallac Victor 2 ELISA reader (PerkinElmer Wallac). Neutraliz-
ing antibodies were determined in cell viability assays as
described previously [23].
Results
The primary objectives of the study were the determination of
the maximum tolerated dose and the dose-limiting toxicity
(grade 4 hematologic toxicity or grade 3 nonhematologic tox-
icity) of scFv(FRP5)-ETA after intravenous application. The
secondary objectives were the determination of the pharma-
cokinetic profile of scFv(FRP5)-ETA, the time to progression,
the objective response rate (complete and partial), and the
immunological response to treatment.
Eighteen patients suffering from ErbB2-expressing metastatic
breast cancers (13 patients), prostate cancers (two patients),
head and neck cancer (one patient), non small cell lung cancer
(one patient), or transitional cell carcinoma (one patient)
(Table 1) were given at least five daily infusions of scFv(FRP5)-
ETA, with total daily doses ranging from 100 µg to 1.4 mg. A
total of 15 patients received the complete treatment cycle of
10 days without showing signs of dose-limiting toxicity,
whereas therapy in three patients was stopped on day 8 due
to a grade 3–4 elevation of liver enzymes (alanine aminotrans-
ferase [ALT], aspartate aminotransferase [AST]) (Table 2). A
dose escalation scheme was pursued, which started at 2 µg/
kg scFv(FRP5)-ETA per treatment day, followed by 4, 10, and
20 µg/kg scFv(FRP5)-ETA. Due to dose-limiting toxicity in two
out of three patients treated at 20 µg/kg scFv(FRP5)-ETA, a
protocol amendment was adopted to include a further dose
level at 12.5 µg/kg scFv(FRP5)-ETA. Five out of six patients atAvailable online http://breast-cancer-research.com/content/7/5/R617
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12.5  µg/kg scFv(FRP5)-ETA received the complete dose
without experiencing severe side effects. In one patient at this
dose level, however, therapy had to be stopped on day 8 due
to toxicity. No objective response was observed in any of the
patients, but two patients remained in stable disease for more
than 3 months, and clinical signs of activity were seen in three
patients.
Toxicity
An increase in the serum levels of liver enzymes was found in
the majority of the patients, with grade 1–2 elevation of ALT or
AST seen in seven patients and grade 1–2 elevation of
gamma-glutamyl transferase in six patients. A dose-limiting tox-
icity with grade 3–4 elevation of ALT or AST was found in two
of three patients treated at 20 µg/kg scFv(FRP5)-ETA and in
one patient treated at 12.5 µg/kg scFv(FRP5)-ETA, resulting
in discontinuation of therapy in these patients on day 8.
Enzyme levels returned to baseline values within 14 days after
cessation of therapy in all patients. One patient with liver
metastases, treated at the lowest dose level (2 µg/kg), devel-
oped cholestasis, which was due to massive disease progres-
sion but was unrelated to treatment, requiring a cessation of
therapy on day 10. Another patient developed fever and dysp-
noe on day 23 after onset of therapy, which resolved with anti-
biotics. However, this patient died on day 40, most probably
unrelated to therapy but due to massive disease progression.
Anti-tumoral efficacy
Complete or partial remissions were not observed after
scFv(FRP5)-ETA treatment, which was not unexpected given
Table 2
Study summary
Patient Dose level (µg/kg) Course of therapy Toxicities ≥  grade 1 Dose-limiting
toxicity
Neutralizing
antibodies
Clinical response
N01 2 According to plan GGT grade 2 No No Progression
U01 2 According to plan None No n.d. Progression
U02 2 Stopped on day 10 Cholestasis due to liver metastasisa No n.d. Progression
N03 4 According to plan GGT grade 2 No No Progression
N04 4 According to plan ALT grade 1 No No Progression
N05 4 According to plan Hemoglobin grade 3a No No Progression
N06 10 According to plan ALT grade 2, AST grade 1 No + Stable disease
N07 10 According to plan ALT/AST grade 1, GGT grade 2 No No Progression
U03 10 According to plan Fever and dyspnoeb No ++ n.d.c
N13 12.5 According to plan ALT grade 1, GGT grade 2, AP grade 1 No No Progression
N14 12.5 Stopped on day 8 ALT/AST grade 3, GGT grade 2, LDH 
grade 1
Yes n.d. n.d.
N15 12.5 According to plan ALT grade 2, AST grade 1, AP grade 2 No + Stable disease
N17 12.5 According to plan ALT/AST grade 2 No No Progression
U04 12.5 According to plan Dyspnoe No No n.d.c
U05 12.5 According to plan None No ++ Progression
N09 20 According to plan ALT/AST grade 2 No +++ Progression
N10 20 Stopped on day 8 ALT grade 4, AST grade 3, GGT grade 2 Yes n.d. n.d.
N12 20 Stopped on day 8 ALT grade 3, AST grade 2 Yes n.d. n.d.c
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; n.d., not determined.
aCausal relationship with study drug unlikely.
bPatient U03 developed fever and dyspnoe after therapy on day 23, which was resolved with antibiotics; the patient died on day 40, causal 
relationship with study drug unlikely.
cClinical signs of activity while on therapy including healing of cutaneous lesion (U03, U04), size reduction of lymph node metastasis (U03), and 
inflammatory response and softening of large tumor mass (N12).Breast Cancer Research    Vol 7 No 5    von Minckwitz et al.
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the severity of the patients' disease and their tumor load. Sta-
ble disease was seen in two patients, however: one prostate
cancer patient treated at 10 µg/kg scFv(FRP5)-ETA per day,
and one breast cancer patient treated at 12.5 µg/kg
scFv(FRP5)-ETA per day. Furthermore, clinical signs of activity
were observed in another three patients, with two patients
treated at 10 and 12.5 µg/kg scFv(FRP5)-ETA per day expe-
riencing signs of healing of cancer-related cutaneous lesions.
In the patient receiving 10 µg/kg scFv(FRP5)-ETA, a reduction
in the size of a cervical lymph node metastasis was also
observed and the morphine dose could be reduced by 50%.
A third patient treated at 20 µg/kg scFv(FRP5)-ETA per day,
despite discontinuation of treatment on day 8 due to dose-
related side effects, demonstrated signs of an inflammatory
response and softening of a large tumor mass in her right
breast. Interestingly, the breast cancer patient with stable dis-
ease and two of the patients with clinical signs of activity had
previously progressed under therapy with trastuzumab (Table
1).
Pharmacokinetic profile
No scFv(FRP5)-ETA could be detected in patient plasma at
the 2 µg/kg dose. At dose levels equal to or greater than 4 µg/
kg scFv(FRP5)-ETA per day, there was a good correlation
between the dose level and the plasma concentration, with
peak levels of scFv(FRP5)-ETA reached 15 min after the
beginning of infusion, and a fast decline to baseline levels
within 4 hours, indicating that the drug was not accumulating
(Fig. 1a). Peak concentrations at steady state (day 5 of ther-
apy) ranged from 18 to 49 ng/ml (mean, 39 ng/ml) at 4 µg/kg
scFv(FRP5)-ETA, ranged from 128 to 129 ng/ml (mean, 129
ng/ml) at 10 µg/kg scFv(FRP5)-ETA, ranged from 93 to 204
ng/ml (mean, 160 ng/ml) at 12.5 µg/kg scFv(FRP5)-ETA, and
ranged from 115 to 307 ng/ml (mean, 236 ng/ml) at 20 µg/kg
scFv(FRP5)-ETA (Fig. 2a). The correlation between the dose
of scFv(FRP5)-ETA and the area under the concentration–
time curve was less pronounced (Figs 1b and 2b). Plasma
clearance was calculated as 6.6 l/hour at 4 µg/kg, as 5.3 l/
hour at 10 µg/kg, as 4.9 l/hour at 12.5 µg/kg, and as 3.8 l/hour
at 20 µg/kg. The calculated half-life of scFv(FRP5)-ETA at the
three higher dose levels was approximately 44 min. The phar-
macokinetic data are summarized in Table 3.
Immunogenicity
Antibody responses to scFv(FRP5)-ETA were analyzed in
detail in 13 patients. None of the patients had pre-existing anti-
bodies reactive with scFv(FRP5)-ETA, but most patients
developed antibodies to scFv(FRP5)-ETA beginning on day 8
after onset of therapy, as determined by ELISA (Fig. 3). Only
in five patients, however, could antibodies with neutralizing
capacity against scFv(FRP5)-ETA be detected in cell viability
assays. A strong neutralizing capacity (neutralizing activity at a
serum dilution of 1:100) was only seen in two patients,
whereas another three patients developed weak or moderate
neutralizing activity (neutralizing activity only at a serum dilution
of 1:50) (data not shown). Clinical symptoms were not associ-
ated with these responses (Table 2).
Discussion
Previous experimental work in various rodent models provided
evidence for efficacy of the recombinant antibody toxin
scFv(FRP5)-ETA against ErbB2-expressing tumors
[9,10,14,16,18,19]. Further support for the use of
Figure 1
(a) Plasma levels of scFv(FRP5)-ETA at steady state (a) Plasma levels of scFv(FRP5)-ETA at steady state. Plasma samples 
were taken from individual patients at each dose level at the indicated 
time points before and after infusion of scFv(FRP5)-ETA on treatment 
day 5. Plasma concentrations were determined by capture ELISA with 
1:10 diluted plasma including standard scFv(FRP5)-ETA concentra-
tions for quantification. No scFv(FRP5)-ETA was detected in the pre-
dose levels, indicating that no accumulation occurred with a once-daily 
dose interval. (b) Area under the concentration–time curve (AUC0–5 
hours) at steady state on treatment day 5 for the different dose levels. 
The area under the concentration–time curve was calculated according 
to the trapezoidal rule from 0 to 5 hours. In accordance with the con-
centration-time profiles there was a dose-dependent increase of the 
area under the concentration–time curve, indicating linear pharmacoki-
netic behavior in the investigated dose range.Available online http://breast-cancer-research.com/content/7/5/R617
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scFv(FRP5)-ETA in tumor therapy arose from a study investi-
gating intratumoral injection of the antibody toxin in patients
with dermal metastases of ErbB2-expressing tumors [23].
Here we report results on the first systemic application of
scFv(FRP5)-ETA in cancer patients, demonstrating safety at
doses up to 12.5 µg/kg per day.
The predominant dose-limiting toxicity encountered in two of
three patients treated at 20 µg/kg was transient liver toxicity,
as indicated by a grade 3–4 elevation of serum liver enzymes
(patient N10, ALT grade 4, AST grade 3; patient N12, ALT
grade 3). An amendment to the protocol was implemented to
test a dose level of 12.5 µg/kg. Liver toxicity (elevation of ALT/
AST grade 3) was observed at this amended dose level in only
one out of six patients. Therefore, 12.5 µg/kg was determined
as the maximum tolerated dose. Liver toxicity can be a com-
mon complication encountered after treatment with recom-
binant toxins based on ETA. This was drastically demonstrated
in a clinical study using erb-38, an ErbB2-specific toxin similar
to scFv(FRP5)-ETA, which consists of a disulfide-bridged Fv
fragment of the ErbB2-specific monoclonal antibody e23
linked to truncated Pseudomonas  toxin [21]. Intravenous
injection of 1 or 2 µg/kg recombinant protein every other day
caused liver toxicity in all patients after 3 days of treatment
[22]. This approximately 10-fold difference in the daily doses
causing liver toxicity when comparing erb-38 with
scFv(FRP5)-ETA might be explained by direct adverse effects
of erb-38 against hepatocytes due to low ErbB2 expression in
the liver, as postulated by Pai-Scherf and colleagues [22].
In tissue culture, scFv(FRP5)-ETA displayed selective cytotox-
icity towards ErbB2-overexpressing tumor cells with IC50 val-
ues in the nanograms per milliliter range [9,17]. While
scFv(FRP5)-ETA and other ErbB2-specific antibody toxins
have not been compared directly, the same cell lines and sim-
ilar assays were used in some studies for in vitro characteriza-
tion. For example, when tested in protein synthesis inhibition
assays, scFv(FRP5)-ETA displayed an IC50  value towards
SKBR3 breast carcinoma cells of 29 ng/ml [9], compared with
a value of 32 ng/ml for e23(Fv)PE40, an ErbB2-specific mole-
cule employing a scFv antibody fragment of e23 for cell target-
ing [20]. Improved cytotoxic activity was reported for erb-38
[21], which might indeed explain the higher degree of toxicity
of this antibody toxin in cancer patients. It is noteworthy, how-
ever, that significantly lower toxicity of scFv(FRP5)-ETA was
also seen in animal experiments, where specific binding to
endogenous ErbB2 on liver cells can be excluded as the
cause for toxicity. ScFv(FRP5)-ETA could be applied intrave-
nously in mice at doses up to 1 mg/kg daily for 10 days without
causing any measurable side effects [19]. This contrasts with
erb-38, for which an LD50 value in mice of 450 µg/kg was
reported after three doses given every other day, and which
caused death of animals by hepatic failure [22].
Various studies link the hepatotoxic effects of Pseudomonas
exotoxin to the increased production of tumor necrosis factor
alpha (TNF-α ) by Kupffer cells in the liver and the resulting liver
damage from activated T cells [27]. Mice depleted of T cells
prior to ETA challenge failed to develop acute hepatic failure,
whereas mice not immunologically compromised demon-
strated hepatocyte apoptosis and increased plasma transami-
nase activity. Furthermore, in mice treated with the ETA-
containing antibody toxin LMB-2, inhibition of TNF-α  produc-
tion in Kupffer cells by a specific TNF-binding protein or
indomethacin prevented LMB-2-induced liver damage [28].
Agents such as infliximab, which neutralize the effects of TNF-
α , are currently in clinical use for the treatment of rheumatoid
arthritis and Crohn's disease [29]. These substances as well
as nonsteroidal anti-inflammatory drugs may also be of use in
preventing some of the unspecific toxic effects of ETA-based
antibody toxins in humans.
Figure 2
Pharmacokinetic parameters for individual patients on treatment day 5 Pharmacokinetic parameters for individual patients on treatment day 5. 
(a) Dose versus peak plasma concentration, Cmax. (b) Dose versus area 
under the concentration–time curve (AUC).Breast Cancer Research    Vol 7 No 5    von Minckwitz et al.
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Generally, cross-reactivity with normal tissues and severity of
adverse reactions might at least in part depend also on the
nature and the position of the epitope recognized by the anti-
body domain [30]. The mAb FRP5 and its scFv derivatives rec-
ognize a peptide epitope located in the N-terminal region of
the receptor [14,31]. In contrast, the humanized ErbB2-spe-
cific antibody Herceptin™ (trastuzumab), which can induce
cardiotoxicity in some patients [32], recognizes the juxtamem-
brane region of ErbB2 [33]. As in a previous study with locally
applied scFv(FRP5)-ETA [23], here we have not observed car-
diovascular complications in any of the patients treated with
scFv(FRP5)-ETA, nor were such toxicities reported for the erb-
38 molecule based on mAb e23 [22], for which information on
the binding epitope is not available.
Our results demonstrate that intravenous administration of
scFv(FRP5)-ETA leads to serum concentrations of the recom-
binant protein over several hours, predicted to be therapeuti-
cally relevant. IC50 values ranging from 10 to 100 ng/ml were
determined in in vitro experiments with human tumor cells
[16]. In the present study a peak serum concentration of 129
ng/ml was found in cancer patients at a dose of 10 µg/kg
scFv(FRP5)-ETA, and serum concentrations between 50 and
100 ng/ml could be maintained for 2 hours after administration
of 12.5 µg/kg scFv(FRP5)-ETA. The calculated half-life of 44
min indicates that the recombinant toxin is rapidly cleared from
the body and is not accumulating. Nevertheless, systemic
treatment with scFv(FRP5)-ETA in mice was successful
despite a relatively short half-life of 30 min in the circulation
[9], suggesting that sufficient amounts of the molecule could
reach the tumor site.
Although objective responses could not be achieved in this
study, clinical signs of activity such as healing of cutaneous
lesions and stable disease were o b s e r v e d  i n  s o m e  o f  t h e
patients treated with scFv(FRP5)-ETA. The lack of major
responses to treatment may be due to the advanced stage of
the patients' disease, the limited treatment time of 2 × 5 days,
or the limited number of patients treated at higher dose levels.
Furthermore, problems with tumor cell accessibility can occur.
Solid tumors of epithelial origin are often poorly vascularized,
possibly limiting the use of large therapeutic molecules such
as antibodies and antibody toxins when administered as a sin-
gle agent. This might explain why most progress has been
made so far in the clinical development of antibody toxins that
target cell surface molecules such as CD22 and CD25
expressed on certain malignancies of hematologic origin
[34,35], where tumor cells are usually more accessible. When
scFv(FRP5)-ETA was directly administered into tumor lesions
by intratumoral injection in a previous study, complete regres-
sion or partial reduction in the size of injected tumor nodules
was found in five out of seven patients with tumors expressing
high ErbB2 levels [23], indicating that the antibody toxin can
very well selectively eliminate ErbB2-overexpressing target
cells if they are accessible.
Antibody responses to scFv(FRP5)-ETA were analyzed in 13
patients. While none of these patients had pre-existing anti-
bodies to ETA, they all developed antibody responses of vary-
ing intensity to scFv(FRP5)-ETA measurable after 8 days of
therapy. Importantly, only in five of the 13 patients analyzed did
these antibodies have scFv(FRP5)-ETA neutralizing activity,
and two of these patients had stable disease for longer than 3
months. The pharmacokinetic parameters shown were deter-
mined on treatment day 5. Thereby a tendency towards a
lower circulation half-life and lower area under the concentra-
tion–time curve values was found when compared with
treatment day 1 (data not shown). This could at least partially
be due to onset of anti-toxin antibody responses. During the
second week of treatment, anti-toxin antibodies might have
affected the half-life of scFv(FRP5)-ETA further, which was not
formally investigated. Nevertheless, in a previous study,
complete remission of tumor nodules locally injected with
scFv(FRP5)-ETA could be achieved after a second treatment
cycle despite pre-existing neutralizing antibodies induced dur-
ing the first round of treatment [23]. Continued treatment of
patients after development of anti-toxin antibodies might there-
fore still be efficacious.
Conclusion
Taken together, our results demonstrate that the ErbB2-spe-
cific antibody toxin scFv(FRP5)-ETA can be safely adminis-
Table 3
Pharmacokinetics of scFv(FRP5)-ETA
Dose level (µg/kg) Peak concentration 
range (ng/ml)
Peak concentration 
mean (ng/ml)
AUC (ng* hour/ml) Plasma clearance (l/
hour)
Half-life (hours)
2 n.d. n.d. n.d. n.d. n.d.
4 18–49 39 ± 18 39 ± 1 6.6 ± 0.6 0.55 ± 0.02
10 128–129 129 ± 1 138 ± 64 5.3 ± 2.1 0.74 ± 0.27
12.5 93–204 160 ± 35 178 ± 100 4.9 ± 3.1 0.73 ± 0.30
20 115–307 236 ± 105 326 ± 146 3.8 ± 2.2 0.73 ± 0.22
AUC, area under the concentration–time curve; n.d., not determined.Available online http://breast-cancer-research.com/content/7/5/R617
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tered intravenously at doses up to 12.5 µg/kg per day to treat
cancer patients with ErbB2-overexpressing tumors. Thereby,
serum concentrations of the drug were reached that could be
of therapeutic value. The major dose-limiting side effect of
scFv(FRP5)-ETA was hepatotoxicity. This may become con-
trollable in future studies by using TNF neutralizing reagents or
by temporary suppression of T-cell activation. Whether the
development of neutralizing antibodies will limit the therapeu-
tic utility of the antibody toxin or whether alternative treatment
schedules or immunosupressant co-medication can overcome
this problem remains unclear at present. To further investigate
the efficacy of systemic scFv(FRP5)-ETA therapy in cancer
patients, we recommend the dose of 12.5 µg/kg for subse-
quent, carefully planned phase II studies.
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